| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/18/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/18/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Agreement and Plan of Merger, by and among Ikena Oncology, Inc., Portsmouth Merger Sub I, Inc., Portsmouth Merger Sub II, LLC, Pionyr Immunotherapeutics, Inc. and Fortis Advisors LLC, as securityholder agent",
"Certificate of Designations of Series A Non-Voting Convertible Preferred Stock",
"Contingent Value Rights Agreement, by and between Ikena Oncology, Inc. and Computershare Trust Company N.A, as rights agent",
"Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction" |
|
| 06/30/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/15/2023 |
8-K
| Investor presentation |
| 05/15/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/10/2023 |
SC 13G/A
| FMR LLC reports a 10.3% stake in IKENA ONCOLOGY INC |
| 01/05/2023 |
4
| Santillana Sergio L. (Chief Medical Officer) has filed a Form 4 on Ikena Oncology, Inc.|
Txns:
| Granted 105,000 options to buy
@ $2.62, valued at
$275.1k
|
|
| 01/05/2023 |
4
| Ecsedy Jeffrey (Chief Development Officer) has filed a Form 4 on Ikena Oncology, Inc.|
Txns:
| Granted 105,000 options to buy
@ $2.62, valued at
$275.1k
|
|
| 01/05/2023 |
4
| Zhang Xiaoyan Michelle (Chief Scientific Officer) has filed a Form 4 on Ikena Oncology, Inc.|
Txns:
| Granted 105,000 options to buy
@ $2.62, valued at
$275.1k
|
|
| 01/05/2023 |
4
| Manfredi Mark (President & CEO) has filed a Form 4 on Ikena Oncology, Inc.|
Txns:
| Granted 220,000 options to buy
@ $2.62, valued at
$576.4k
|
|
| 01/05/2023 |
4
| Marango Jotin (CFO & Head of Corp. Dev.) has filed a Form 4 on Ikena Oncology, Inc.|
Txns:
| Granted 105,000 options to buy
@ $2.62, valued at
$275.1k
|
|
| 12/19/2022 |
4
| Hughes Owen (Director) has filed a Form 4 on Ikena Oncology, Inc.|
Txns:
| Granted 35,040 options to buy
@ $2.62, valued at
$91.8k
|
|
| 12/19/2022 |
3
| Hughes Owen (Director) has filed a Form 3 on Ikena Oncology, Inc. |
| 12/19/2022 |
8-K
| Quarterly results |
| 11/28/2022 |
8-K
| Investor presentation |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/11/2022 |
SC 13G/A
| FMR LLC reports a 7% stake in IKENA ONCOLOGY INC |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|